Do you have a patient like Ray?*
Ray has advanced HCC and AFP ≥400 ng/mL*
A patient whose aggressive disease progressed on 1L therapy
A patient who is determined to continue treatment
- Presents with NASH
- Diagnosed with advanced HCC
- Discontinued sorafenib treatment due to disease progression
- Serum AFP level of 623 ng/mL
- Child-Pugh class A
- ECOG PS 1
A patient who knows he has to work hard and needs a treatment that can work on his HCC
When you see a patient with HCC and AFP ≥400 ng/mL, you can identify a treatment studied specifically for them1-3
SELECT IMPORTANT SAFETY INFORMATION
- CYRAMZA increased the risk of hemorrhage and gastrointestinal hemorrhage, including Grade ≥3 hemorrhagic events. Across five clinical studies in 1916 patients with various cancers treated with CYRAMZA, the incidence of all Grade hemorrhage occurred between 13-44%. Grade 3-5 hemorrhage incidence ranged from 2-5%.
- Permanently discontinue CYRAMZA in patients who experience severe (Grade 3 or 4) bleeding.